| BD (n = 20) | Controls (n = 20) | Statistics |
---|---|---|---|
Mood stabilizers | |||
 Lithium | 30% | – |  |
 Atypical antipsychotics | 35% | – |  |
 Anticonvulsants | 10% | – |  |
 Others | 25% | – |  |
Somatic comorbidities | |||
 Cardiovascular disease | 5 | 0 | χ2(1) = 5.71, p = 0.017a |
 Diabetes mellitus | 3 | 0 | χ2(1) = 3.24, p = 0.231a |
 Obstructive pulmonary disease | 2 | 0 | χ2(1) = 2.11, p = 0.487a |
 Hypertension | 6 | 2 | χ2(1) = 2.50, p = 0.114 |
Symptom self-ratings | |||
 BDI-2 (M, SD), April | 15.45 (10.74) | 3.10 (2.53) | t(38) = 5.00, p < 0.001 |
 BDI-2 (M, SD), May | 12.20 (11.69) | 2.40 (2.21) | t(38) = 3.69, p < 0.01 |
 ASRM (M, SD), April | 0.95 (2.28) | 0.55 (1.19) | t(38) = 0.70, p = 0.491 |
 ASRM (M, SD), May | 1.5 (2.19) | 0.25 (0.55) | t(38) = 2.48, p = 0.022 |